Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; Department of Radiology, Shanxi Provincial People's Hospital, Taiyuan, China.
GE Healthcare China, Beijing, China.
Diagn Interv Radiol. 2021 May;27(3):440-449. doi: 10.5152/dir.2021.20154.
We aimed to explore whether multiparametric magnetic resonance imaging (MRI)-based radiomics combined with selected blood inflammatory markers could effectively predict the grade and proliferation in glioma patients.
This retrospective study included 152 patients histopathologically diagnosed with glioma. Stratified sampling was used to divide all patients into a training cohort (n=107) and a validation cohort (n=45) according to a ratio of 7:3, and five-fold repeat cross-validation was adopted in the training cohort. Multiparametric MRI and clinical parameters, including age, the neutrophil-lymphocyte ratio and red cell distribution width, were assessed. During image processing, image registration and gray normalization were conducted. A radiomics analysis was performed by extracting 1584 multiparametric MRI-based features, and the least absolute shrinkage and selection operator (LASSO) was applied to generate a radiomics signature for predicting grade and Ki-67 index in both training and validation cohorts. Statistical analysis included analysis of variance, Pearson correlation, intraclass correlation coefficient, multivariate logistic regression, Hosmer-Lemeshow test, and receiver operating characteristic (ROC) curve.
The radiomics signature demonstrated good performance in both the training and validation cohorts, with areas under the ROC curve (AUCs) of 0.92, 0.91, and 0.94 and 0.94, 0.75, and 0.82 for differentiating between low and high grade gliomas, grade III and grade IV gliomas, and low Ki-67 and high Ki-67, respectively, and was better than the clinical model; the AUCs of the combined model were 0.93, 0.91, and 0.95 and 0.94, 0.76, and 0.80, respectively.
Both the radiomics signature and combined model showed high diagnostic efficacy and outperformed the clinical model. The clinical factors did not provide additional improvement in the prediction of the grade and proliferation index in glioma patients, but the stability was improved.
本研究旨在探讨基于多参数磁共振成像(MRI)的放射组学与选定的血液炎症标志物相结合,能否有效预测胶质瘤患者的分级和增殖情况。
本回顾性研究纳入了 152 例经组织病理学诊断为胶质瘤的患者。根据 7:3 的比例对所有患者进行分层抽样,分为训练队列(n=107)和验证队列(n=45),并在训练队列中采用五重交叉验证。评估多参数 MRI 和临床参数,包括年龄、中性粒细胞-淋巴细胞比值和红细胞分布宽度。在图像处理过程中,进行图像配准和灰度归一化。通过提取 1584 个基于多参数 MRI 的特征进行放射组学分析,然后应用最小绝对值收缩和选择算子(LASSO)在训练和验证队列中生成用于预测分级和 Ki-67 指数的放射组学特征。统计分析包括方差分析、Pearson 相关分析、组内相关系数、多变量逻辑回归、Hosmer-Lemeshow 检验和受试者工作特征(ROC)曲线。
放射组学特征在训练和验证队列中均表现出良好的性能,用于区分低级别和高级别胶质瘤、III 级和 IV 级胶质瘤以及低 Ki-67 和高 Ki-67 的 ROC 曲线下面积(AUC)分别为 0.92、0.91 和 0.94,0.94、0.75 和 0.82,优于临床模型;联合模型的 AUC 分别为 0.93、0.91 和 0.95,0.94、0.76 和 0.80。
放射组学特征和联合模型均表现出较高的诊断效能,优于临床模型。临床因素并未在预测胶质瘤患者的分级和增殖指数方面提供额外的改善,但提高了稳定性。